CLOMID
LOE ApproachingNDAORALTABLETPriority Review
Approved
Feb 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
CLOMID by Sanofi is clinical pharmacology action clomiphene citrate is a drug of considerable pharmacologic potency. Approved for ovulatory dysfunction in women desiring pregnancy. First approved in 1967.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLOMID (clomiphene citrate) is an oral small-molecule estrogen-receptor modulator approved in 1967 for treatment of anovulatory infertility. It works by competing with estrogen for receptor binding in the hypothalamus and pituitary, triggering a cascade of gonadotropin release that stimulates ovulation. The drug has mixed estrogenic and antiestrogenic properties that collectively initiate the preovulatory LH surge and follicular rupture.
$0.564MPart D
LOE ApproachingProduct is approaching loss of exclusivity with minimal Part D spending ($564K in 2023), indicating small commercial footprint and likely reduced team expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Action Clomiphene citrate is a drug of considerable pharmacologic potency. With careful selection and proper management of the patient, clomiphene citrate has been demonstrated to be a useful therapy for the anovulatory patient desiring pregnancy. Clomiphene citrate is capable…
Worked on CLOMID at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.